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Abstract
Background: Cycling and chronic tumor hypoxia are involved in tumor development and growth. However, the impact of
cycling hypoxia and its molecular mechanism on glioblastoma multiforme (GBM) progression remain unclear.
Methodology: Glioblastoma cell lines, GBM8401 and U87, and their xenografts were exposed to cycling hypoxic stress in
vitro and in vivo. Reactive oxygen species (ROS) production in glioblastoma cells and xenografts was assayed by in vitro ROS
analysis and in vivo molecular imaging studies. NADPH oxidase subunit 4 (Nox4) RNAi-knockdown technology was utilized
to study the role of Nox4 in cycling hypoxia-mediated ROS production and tumor progression. Furthermore, glioblastoma
cells were stably transfected with a retroviral vector bearing a dual reporter gene cassette that allowed for dynamic
monitoring of HIF-1 signal transduction and tumor cell growth in vitro and in vivo, using optical and nuclear imaging.
Tempol, an antioxidant compound, was used to investigate the impact of ROS on cycling hypoxia-mediated HIF-1 activation
and tumor progression.
Principal Findings: Glioblastoma cells and xenografts were compared under cycling hypoxic and normoxic conditions;
upregulation of NOX4 expression and ROS levels were observed under cycling hypoxia in glioblastoma cells and xenografts,
concomitant with increased tumor cell growth in vitro and in vivo. However, knockdown of Nox4 inhibited these effects.
Moreover, in vivo molecular imaging studies demonstrated that Tempol is a good antioxidant compound for inhibiting
cycling hypoxia-mediated ROS production, HIF-1 activation, and tumor growth. Immunofluorescence imaging and flow
cytometric analysis for NOX4, HIF-1 activation, and Hoechst 3342 in glioblastoma also revealed high localized NOX4
expression predominantly in potentially cycling hypoxic areas with HIF-1 activation and blood perfusion within the
endogenous solid tumor microenvironment.
Conclusions: Cycling hypoxia-induced ROS via Nox4 is a critical aspect of cancer biology to consider for therapeutic
targeting of cycling hypoxia-promoted HIF-1 activation and tumor progression in GBM.
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Introduction
Tumor hypoxia is a crucial microenvironmental condition that
promotes tumor progression and resistance to chemo- or
radiotherapy [1,2,3]. It has been classified into 2 types. Acute
hypoxia is associated with inadequate blood flow while chronic
hypoxia is the consequence of increased oxygen diffusion distance
due to tumor expansion. Temporal instability in oxygen transport
has classically been termed ‘‘intermittent’’ or ‘‘acute’’ hypoxia [4].
Recent review articles have summarized the overall features of the
oxygenation state within tumors and have used the term ‘‘cycling
hypoxia’’ to describe the cyclical features of intermittent or acute
hypoxia in tumor hypoxia [5]. It has long been thought that
chronic hypoxia, rather than acute hypoxia, plays the main role in
promotion of cancer progression and in the efficacy of radiation
therapy or chemotherapy [1], because the major phenotypic shift
associated with chronic hypoxia involves tumor cell resistance to
chemotherapy or radiotherapy, in addition to more invasive and
metastatic features. However, there is ample evidence to suggest
that cycling hypoxia also influences many aspects of tumor
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have made oncologists aware of the potential role of cycling
hypoxia in tumor progression and treatment.
Cycling hypoxia modulates tumor growth, angiogenic processes,
metastasis, and radioresistance in several tumor models [6,7,8].
However, some phenotypes seem to be dependentupon tumortype.
Different tumor types have distinct effects on cycling hypoxia-
mediated tumor progression. To our knowledge, the impact of
cycling hypoxia on tumor progression in glioblastoma multiforme
(GBM) has not been investigated. Although the detailed mechanism
is still undefined, earlier studies have suggested that reactive oxygen
species (ROS) and hypoxia-inducible transcription factor 1a (HIF-
1a) are potential mediators of cycling hypoxia-mediated tumor
progression and radiotherapy resistance [4,5]. ROS and HIF-1a
wereshowntobethekeymediatorsoftumorangiogenesis,invasion,
and metastasis [9,10]. However, the lack of direct evidence from the
in vivo tumor microenvironment is a significant impediment to
supporting this notion.
ROS are produced during cycling hypoxia and leads to tumor
progression, but the mechanisms of ROS generation and the
targets of ROS signals are not well understood. Nox-family
NADPH oxidases have proven to be a major source of ROS
production in various cell types and have crucial roles in various
physiological and pathological processes [11]. Recent studies have
demonstrated that NADPH oxidase subunit 4 (Nox4) is expressed
in several tumor types such as hepatoma [12], breast cancer [13],
ovarian cancer [14], melanoma [15], prostate cancer [16], and
various neuroepithelial neoplasms [17], and is involved in cellular
senescence, resistance to apoptosis, tumorigenic transformation,
cell proliferation, cell survival, and radiation resistance. Strong
evidence suggests that these processes are upregulated via Nox4
generation of ROS. Nox4 can also serve as an oxygen sensor to
regulate TASK-1 enzyme activity [18] and HIF activity [19].
Based on these data, we hypothesized that Nox4 might be a critical
mediator of cycling hypoxia-mediated ROS generation and tumor
progression in GBM.
The purpose of this study is to explore the impact of cycling
hypoxia on GBM progression and to investigate the potential
mechanism of this process using molecular biology and imaging
techniques. We have now shows that cycling hypoxic stress
significantly increases ROS production, HIF-1 activation, and
tumor growth in vitro and in vivo. Our results also indicate that
Nox4 is a critical mediator of these processes and its expression
tends to occur in potential cycling hypoxic areas with HIF-1
activation and blood perfusion within the endogenous tumor
microenvironment.
Materials and Methods
Cell culture
GBM8401 and U87 were cultured in DMEM (Life Technol-
ogies) supplemented with 10% fetal bovine serum (FBS), 10 mM
HEPES, and 1% penicillin-streptomycin.
In vitro hypoxic treatments
The cells were treated in a Biospherix C-Chamber (Biospherix)
inside a standard culture chamber by means of exhausting and
gassing with 95% N2 and 5% CO2 to produce oxygen
concentrations of 0.5 to 1% for 4 h at 37uC to achieve non-
interrupted hypoxic conditions. For the cycling hypoxic treatment,
cell cultures were exposed to 12 cycles of 0.5 to 1% O2 for 10 min
interrupted by 5% CO2 and air for 10 min at 37uC in a hypoxia
chamber with a timer-controlled regulator. In vitro medium oxygen
during cycling hypoxia was determined using the Oxford Oxylite
fiberoptic probe (Oxford) and this condition resulted in the
medium pO2 of 0.8–1.5 mmHg during hypoxic phase
In vitro ROS production
ROS production was assessed by using 10-acetyl-3,7-dihydrox-
yphenoxazine (Amplex Red, Molecular Probes) to evaluate H2O2
or carboxy-2979-dihydrodichlorofluorescein diacetate (H2DCFDA,
Molecular Probes) to assess total ROS. Cells were incubated in
phenol-freemediuminthe presenceof50 mmol/LAmplexRedand
0.1 U/mL horseradish peroxidase or 10 mM H2DCFDA under in
vitro hypoxic treatments. Fluorescence was measured in a Spec-
traMax M2/M2e Microplate Reader (Molecular Devices) with
excitation at 530 nm and emission at 590 nm for Amplex Red or
excitation at 485 nm and emission at 520 nm for H2DCFDA.
Real-time quantitative PCR
Q-PCR analysis was performed as described previously [20].
The primers for quantitative analysis of Nox4 and the housekeep-
ing gene 60S acidic ribosomal proteins were: Nox4 (F) 59-
ACAGGGGTCTGCATGGTGGT-39 and (R) 59-GCAGCCCT-
CCTGAAACATGC-39; and the house keeping gene 60S acidic
ribosomal protein (F) 59-ACGAGGTGTGCAAGGAGGGC-39
and (R) 59-GCAAGTCGTCTCCCATCTGC-39.
Western blot analysis
Whole cell and nuclear extracts were prepared as described
previously [20]. Nox4 protein in GBM cells was detected in
150 mg of cell extract by using a monoclonal Nox4 antibody
(1:650; Novus). Nuclear extracts were examined for HIF-1
activation using a monoclonal HIF-1a antibody (1:750; Novus).
Western blots were normalized using a monoclonal anti-b-actin
antibody for cell extracts (diluted 1:10,000; Santa Cruz Technol-
ogy) and a monoclonal anti-TATA binding protein (TBP) (diluted
1:2,000; Abcam) for nuclear extracts.
Small interfering RNA transfection
GBM8401 or U87 cells were transfected with Nox4 small
interfering RNA (siRNA) (Santa Cruz Biotechnology) using the
OligofectAMINE transfection reagent (Invitrogen) according to
the manufacturer’s instructions.
Vector constructions and viral transduction
The lentiviral vector pLKO AS2 (National RNAi Core Facility,
Taiwan) served as the backbone to generate a lentiviral vector
bearing a luciferase (Luc) reporter gene. The Luc gene was PCR-
amplified from pTA-Luc (Clontech) and inserted into pLKO AS2
under the cytomegalovirus (CMV) promoter at the NheI and
EcoRI restriction sites. We used PCR cloning to insert the
NESTKGFP:dMODC [20] fusion reporter gene in place of the
original TKGFP fusion reporter gene in dxHRE-tk/eGFP-
cmvRed2XPRT [21]. The lentiviral vector pLVCT-tTR-KRAB
(Addgene) was used to express Nox4 shRNA (Sigma) following
the manufacturer’s protocol. Lentivirus or retrovirus production
and cell transduction were carried out according to protocols
described elsewhere [21,22]. The GBM8401 and U87 cells
bearing the Luc reporter gene and the dual reporter gene cassette
were termed GBM8401-Luc or U87-Luc and GBM8401/hif-1-r
or U87/hif-1.
Animal models
Eight-week-old female athymic nu/nu mice were used to
establish animal tumor models. For the subcutaneous GBM
xenograft model, 5610
6 GBM8401-Luc or GBM8401/hif-1-r
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tion were injected subcutaneously into the dorsal aspects of the left
anterior limbs and small (80616.0 mm
3) subcutaneous tumors
developed 14 days later were used for animal imaging studies. For
the orthotopic GBM xenograft model, the procedure was carried
out following published methods [23]. Briefly, 2610
5 GBM8401-
Luc cells or GBM8401/hif-1-r cells were harvested by trypsiniza-
tion and injected into the right basal ganglia of anesthetized mice.
Mice bearing the orthotopic GBM8401-Luc or GBM8401/hif-1-r
xenograft after 12 days were used for in vivo cycling hypoxic stress
studies. All animal studies were conducted according to the
Institutional Guidelines of China Medical University and
approved by the Institutional Animal Care and Use Committees
of China Medical University (approval number 97-65-N).
Animal treatments
Mice bearing the orthotopic GBM8401 reporter xenograft
received drinking water containing 5% sucrose only (control), 5%
sucrose plus 300 mg/mL Tempol (Tempol treatment), or 5%
sucrose plus 2 mg/mL Dox (knockdown) and 24 d of in vivo cycling
hypoxia. Tumor progression was monitored by weekly biolumi-
nescence imaging and mice were monitored daily for survival. The
procedure for in vivo cycling hypoxic treatment was carried out
following published methods [7,8]. Briefly, the tumor-bearing
mice were exposed to continuous flow of a humidified gas mixture
to induce in vivo hypoxia in 6-liter hypoxia chambers. The mice
were exposed to normal air (control) or 7% O2 for 4 h for non-
interrupted hypoxic treatment or 12 cycles of 10 min 7% O2
breathing interrupted by 10 min periods of normal air breathing
for cycling hypoxic treatment. Tumor oxygen was determined
with an Oxford Oxylite fiberoptic probe (Oxford) and this
condition resulted in the tumor pO2 of 1.2–2.5 mm Hg during
hypoxic phase. At least 6 mice were used for each cohort. Animals
exhibiting significant neurologic compromise, such as limping, or
any significant paresis that impaired the ability to obtain food,
were euthanized with carbon dioxide gas.
Animal imaging
The luminescent probe L-012 (Wako Chemical) was adminis-
tered intravenously (40 mg/kg) after in vivo hypoxic treatments for
in vivo ROS analysis [24]. At 5 min after probe administration,
luminescence from the animals was recorded with the IVIS
Imaging System 200 Series (Caliper Life Sciences). To image HIF-
1 activity, mice were injected with 9.25610
6 Bq
18F-9-(4-fluoro-3-
hydroxymethyl- butyl) guanine (FHBG) and imaged on a small-
animal PET scanner (microPET; Concorde Microsystems) [20]. In
vivo GFP and DsRed expression were measured in an IVIS
imaging system 200 series with excitation at 445–490 nm and
emission at 515–575 nm for GFP or excitation at 500–550 nm
and emission at 575–650 nm for DsRed. The image capture
condition was set up as binning (868), f2, FOV13, 3 s. Signal
intensity after background subtraction was quantified by Living
Imaging software. For in vivo bioluminescence imaging (BLI) of
tumor progression, mice were anesthetized with isoflurane and
imaged 15 min after intraperitoneal injection of luciferin. Signal
intensity was quantified within a region of interest over the head
that was defined with LivingImage software.
Immunofluorescence imaging
A perfusion marker, Hoechst 33342 (1 mg/mouse; Sigma), was
intravenously (i.v.) administered 30 min prior to tumor excision.
Tumor tissues were frozen in the OCT embedding matrix
(Shandon Lipshaw). Frozen tissue sections (10 mm) were obtained
with an OTF cryomicrotome (Bright-Hacker), fixed in ice-cold
methanol for 10 min, and washed with PBS. Tumor sections were
co-stained for Nox4 by including Nox4 antibody (Novus) at a final
concentration of 10 mg/mL. Sections were washed 3 times in PBS,
each wash lasting 5 min. For Nox4 staining, sections were
incubated with DyLght 649-conjugated goat anti-rabbit antibody
(1:100; Molecular Probes) and washed again. Tissue fluorescence
was visualized with the Axio Observer A1 digital fluorescence
microscope system (ZEISS).
Flow cytometry
Tumor tissues were disaggregated with an enzyme cocktail
containing collagenase type III (Sigma), hyaluronidase (Sigma),
and collagenase type IV (Sigma), washed several times, and
resuspended in phosphate-buffered saline (PBS) to produce a single
cell suspension. Prior to flow cytometry, cells were incubated with
rabbit polyclonal anti-Nox4 antibody in cold fluorescence-
activated cell sorting (FACS) buffer (PBS, 0.5% BSA) on ice for
30 min. After washing in FACS buffer, cells were incubated with
DyLght 649-conjugated goat anti-rabbit antibody. After the final
washing step, fluorescence was measured using a FACScalibur
instrument and FACSDiva 6.0 software (BD Bioscience). Tumor
cells were gated according to DsRed expression and side scatter
(SSC). Nox4 expression was further evaluated after Hoechst 3342
and GFP gating on cycling hypoxic tumor cells (DsRed
+, Hoechst
3342
+, and GFP
+), chronic hypoxic tumor cells (DsRed
+, Hoechst
3342
2 and GFP
+), or normoxic tumor cells (DsRed
+, Hoechst
3342
+, and GFP
2).
Immunohistochemistry
Tumor tissues were fixed in 4% paraformaldehyde and
embedded in OCT compound. Five micrometer sections were
immunostained with mouse monoclonal anti-Nox4 (Novus
Biologicals), visualized with an AEC kit (InnoGenex), and
counterstained with hematoxylin.
Statistical analysis
For multiple comparisons of nonparametric variables, Kruskal-
Wallis ANOVA was used. For parametric variables, ANOVA was
used along with Fisher’s least-significant-difference (LSD). For
survival analysis, statistical software for Kaplan-Meier Survival
Analysis with Tarone-Ware statistics (SPSS Inc) was used. P,0.05
was considered significant. All analyses were two-tailed.
Results
Cycling hypoxia triggers ROS production via Nox4 in
glioblastoma cells
We first examined the effect of experimentally imposed non-
interrupted or cycling hypoxic stress on ROS production and
Nox4 expression. An increasing fluorescent signal was observed in
cycling hypoxia-treated GBM8401 and U87 cells (Fig. 1A and B).
In contrast to cycling hypoxia treated-cells, no significant increase
in ROS levels was found in normoxic or non-interrupted hypoxic
cells. Furthermore, Q-PCR and western blot analysis also showed
significantly increased levels of Nox4 mRNA and protein were
expressed in cycling hypoxia-treated cells (Fig. 1C and D). To
study the source of ROS generation in cycling hypoxia, we used a
specific silencing siRNA to knockdown Nox4 induction in
GBM8401 and U87 cells under cycling hypoxia. RT-PCR and
western blot analysis showed that this siRNA successfully knocked
down Nox4 expression, whereas the negative control (Neg)
siRNAs did not (Fig. 1C and D). Cycling hypoxia-induced ROS
was inhibited by Nox4 knockdown and by treatment with the
NADPH oxidase inhibitor diphenyleneiodonium chloride (DPI,
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production via Nox4 in glioblastoma cells.
Nox 4 knockdown and antioxidant compound suppress
cycling hypoxia-induced ROS levels in glioblastoma
xenografts
Having linked cycling hypoxia with ROS production, we next
sought to determine whether Nox4 knockdown or treatment with
an antioxidant compound can suppress cycling hypoxia-induced
ROS levels in glioblastoma xenografts. We first utilized tetracy-
cline-inducible lentiviral vectors encoding shRNAs to stably and
specifically knockdown Nox4 in GBM8401-Luc cells. These cells
expressed a low level of Nox4 in the presence of Dox (Fig. 2A).
The Nox4 immunohistochemical analysis in GBM8401-Luc
xenografts demonstrated that Dox induction of shRNAs targeting
Nox4 in vivo also led to suppression of Nox4 expression in
glioblastoma tumors (Fig. 2B). As shown in Fig. 2C and D, the
ROS levels were significantly higher in cycling hypoxia-pretreated
glioblastoma tumors than in control tumors. However, Nox4
knockdown or Tempol treatment in glioblastoma xenografts under
cycling hypoxic stress inhibited additional cycling hypoxia and
endogenous tumor microenvironment-induced ROS production.
These results suggest that cycling hypoxia generates oxidative
stress to produce ROS within the tumor microenvironment. Nox4
knockdown or Tempol treatment in vivo suppresses cycling
hypoxia-induced ROS levels in glioblastoma.
Cycling hypoxia induces high, long-term HIF-1 activation
in vitro and in vivo
The amount of HIF-1a protein in nuclear extracts was assayed
by Western blot analysis after 4 h of in vitro hypoxic treatment.
Both non-interrupted and cycling hypoxic stress caused GBM8401
and U87 cells to increase expression of HIF-1a protein. However,
HIF-1a protein levels in GBM8401 and U87 cells under cycling
hypoxic stress were higher than in cells under non-interrupted
hypoxic stress (Fig. 3A). We next verified whether this effect could
further induce differential HIF-1 signal transduction. As shown in
Fig. 3B, transcriptional activity at the hypoxia-responsive elements
(HRE) in cycling hypoxia-treated GBM8401/hif-1-r was signifi-
cantly higher than in the non-interrupted hypoxia-treated group.
We then sought to validate our in vitro findings in GBM xenografts.
In vivo optical imaging was used to record reporter activity in 14-
day GBM xenografts in mice following in vivo hypoxic treatments.
Time-course data showed that HIF-1 signal transduction increased
Figure 1. Cycling hypoxia triggers ROS production via Nox4 in glioblastoma cells. GBM8401 and U87 cells were treated with cycling
hypoxic stress for 4 h in the absence or presence of Nox4 siRNA or 10 mM diphenyleneiodonium chloride (DPI), and the levels of intracellular ROS (A),
H2O2 (B), Nox4 mRNA (C), and Nox4 protein (D) were evaluated by H2DCHFDA reagent, Amplex Red assay, Q-PCR, and western blotting, respectively.
Each bar represents the mean 6 standard deviation of triplicate measurements. * p,0.01 compared to normoxia. # p,0.01 compared to cycling
hypoxia.
doi:10.1371/journal.pone.0023945.g001
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hypoxic stress and at 48–72 h after cycling hypoxic stress (Fig. 3C).
These data indicate that cycling hypoxic stress results in
significantly prolonged elevation of HIF-1 signal transduction in
glioblastoma cells.
ROS is required for cycling hypoxia-induced HIF-1
activation in vitro and in vivo
To investigate whether ROS is required for cycling hypoxia-
induced HIF-1 activation, GBM8401/hif-1-r and U87/hif-1-r
cells were treated with Tempol over a 4-h period of cycling
hypoxia treatment and Tempol prevented ROS generation in
these conditions (Fig. 1A and B). FACS demonstrated that HIF-1
signal transduction activity in the cycling hypoxia-treated cells
increased steadily after treatment (Fig. 4A). Tempol treatment
following cycling hypoxia abrogated the increase in HIF-1 signal
transduction. We then sought to verify our in vitro findings in vivo.
MicroPET and in vivo optical imaging studies demonstrated that
mice bearing GBM8401/hif-1-r xenografts under cycling hypoxic
stress had significantly higher [
18F]FHBG accumulation and
fluorescence intensity in GBM tumors compared to control mice
(Fig. 4B and C; Table 1). Moreover, the cycling hypoxia-induced
[
18F]FHBG accumulation and fluorescence intensity in GBM
tumors was inhibited by Tempol treatment. These results indicate
that ROS are required for cycling hypoxia-induced HIF-1
activation, and Tempol is an effective ROS inhibitor for blocking
cycling hypoxia-mediated HIF-1 activation.
The majority of HIF-1 signal transduction activity and
Nox4 expression occurs in endogenous cycling hypoxic
areas in solid tumor
To investigate the biosignature of Nox4 expression and HIF-1
signal transduction within the tumor microenvironment, mice
bearing 18-d orthotopic GBM8401/hif-1-r xenografts were
injected intravenously with a perfusion marker (Hoechst 33342)
and the tumors were removed for tissue immunofluorescence
imaging. Tight colocalization of higher GFP intensity and Hoechst
33342 signals was observed (Fig. 5A), indicating that the majority
of HIF-1 signal transduction occurs in areas with relatively high
perfusion. Areas with positive Hoechst 33342 staining and GFP
expression were also potential cycling hypoxic areas. However,
areas that were positive for GFP expression but negative for
Figure 2. Nox 4 knockdown and a antioxidant compound suppress cycling hypoxia-induced ROS levels in glioblastoma xenografts.
(A) Regulation of Nox4 by Dox-inducible shRNA. GBM8401-Luc cells were infected with Tet-regulable lentiviral vectors encoding Nox4 shRNAs. The
infected cells were treated with or without Dox for 24 h and harvested for western blot analysis. (B) Immunohistochemical analysis of Nox4 in
GBM8401-Luc xenografts with or without conditional knockdown of Nox4 under cycling hypoxic stress. Original magnification,6200. Bar, 100 mm. (C)
In vivo optical imaging of GBM-bearing mice injected with L-012. (D) Quantitative data obtained from in vivo optical imaging of ROS levels in GBM
xenografts with or without Dox or Tempol following in vivo cycling hypoxic stress. * p,0.01 compared to normoxia. # p,0.01 compared to cycling
hypoxia.
doi:10.1371/journal.pone.0023945.g002
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Nox4 expression tended to occur in the cycling hypoxic areas but
not in the chronic hypoxic areas. To better verify endogenous
tumor microenvironment-mediated HIF-1 activation and Nox4
expression in the solid tumor, we identified subpopulations of
tumor cells from GBM8401/hif-1-r xenografts based on differen-
tial Hoechst 33342 and GFP fluorescence and investigated Nox4
expression in these subpopulations using flow cytometry. As
illustrated in Fig. 5B, the tumor suspension consisted of
approximately 2864% cycling hypoxic cells (Hoechst 3342
+ and
GFP
+), 1062% chronic hypoxic cells (Hoechst 3342
2 and GFP
+),
and 5866% normoxic cells (Hoechst 3342
+ and GFP
2).
Moreover, Nox4 expression was significantly higher in cycling
hypoxic cells than in chronic hypoxic cells or normoxic cells
(Fig. 5C). These results suggest that the majority of HIF-1 signal
transduction activity and Nox4 expression occurs in areas of
endogenous cycling hypoxia in solid tumors.
Cycling hypoxia promotes tumor growth via Nox4-
mediated ROS
We utilized BLI for assessing intracranial tumor response to
cycling hypoxia, Nox4 knockdown, and Tempol treatment in the
orthotopic GBM8401-Luc xenograft model. There was a highly
significant increase in tumor growth rate in the group receiving
cycling hypoxia treatment compared to the control group (Fig. 6A).
Both cycling hypoxia-pretreated mice and control mice treated
with Dox or Tempol showed inhibition of tumor growth. Our
results also demonstrated that the mean survival time in cycling
hypoxia-pretreated mice was significant lower than in control mice
(Fig. 6B). Dox or Tempol treatment significantly prolonged the
survival of cycling hypoxia-pretreated mice and normoxic mice. In
summary, Nox4 knockdown and Tempol treatment during GBM
progression may be a therapeutic approach to block the impact of
cycling hypoxia on tumor progression.
Discussion
Hypoxia and reoxygenation are distinct stimuli capable of
stimulating ROS formation. Hypoxia stimulates ROS formation
from mitochondria [25] and xanthine oxidase [26], whereas re-
oxygenation induces NADPH oxidase-derived ROS formation
[27]. However, little is known of the difference in tumor ROS
levels between cycling hypoxia and non-interrupted hypoxia and
the oxygen sensor that regulates ROS production in the tumor
microenvironment has not been identified. Recent studies have
demonstrated that Nox proteins are expressed in many cell types
and tissues [28]. Their expression and function varies from tissue
to tissue. Nox-based oxidases promote cancer development and
overproduction of intracellular ROS is thought to increase the risk
of cancer [29]. In the present study, in vitro and in vivo ROS analysis
clearly showed that cycling hypoxia could induce more ROS
production than normoxia in GBM cells and xenografts. We also
examined the role of Nox4 in cycling hypoxia-induced ROS
production because it has been suggested that Nox4 is expressed in
human glioma [17]. The following evidence demonstrates that
Nox4 is essential for cycling hypoxia-induced ROS production.
First, cycling hypoxia induced Nox4 mRNA and protein
expression in GBM cells. Second, up-regulation of Nox4
expression tended to occur in the cycling hypoxic areas of the
Figure 3. Cycling hypoxia induces higher, long-term HIF-1 activation in glioblastoma cells and xenografts. (A) Western blot analysis of
HIF-1a in GBM8401 and U87 cells after cycling hypoxia. Cells were exposed to hypoxic stress, either non-interrupted or cycling, for 4 h and harvested to
determine the amounts of HIF-1a protein in nuclear extracts. (B) Transcriptional activity at hypoxia response elements in GBM8401 cells after cycling hypoxic
stress. GBM8401/hif-1-r cells were cultured under hypoxic stress, either non-interrupted or cycling, for 4 h and grown in normoxia for different periods,
followed by measurements of reporter gene expression. (C) Kinetics of HIF-1 transcriptional activity in GBM8401/hif-1-r xenografts after cycling hypoxic stress.
In vivo fluorescence imaging (FLI) was performed for GBM8401/hif-1-r tumors before hypoxic treatments and at different times after hypoxic treatments. The
data represent the mean 6 standard deviation of the ratio of average counts within the tumor region of interest (ROI) in GFP and DsRed signals from 6 mice.
doi:10.1371/journal.pone.0023945.g003
Figure 4. ROS is required for cycling hypoxia-induced HIF-1
activation in glioblastoma cells and xenografts. (A) Flow
cytometric analysis of HIF-1 transcriptional activity in GBM8401/hif-1-r
and U87/hif-1-r cells exposed to cycling hypoxic stress with or without
Tempol. In vivo microPET imaging (B) and in vivo optical imaging (C) of
HIF-1 transcriptional activity in GBM8401/hif-1-r tumors with or without
Tempol treatment. MicroPET imaging with [
18]FHBG and in vivo optical
imaging were used to determine in vivo HIF-1 signal transduction
activity 24 h after in vivo cycling hypoxia treatment.
doi:10.1371/journal.pone.0023945.g004
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treatment suppressed cycling hypoxia-induced ROS generation.
We conclude that Nox4 is a critical mediator of the tumor
microenvironment under cycling hypoxia, and mediates ROS
production in GBM.
GBM tumors may contain numerous hypoxic areas that exhibit
elevated HIF-1 signal transduction activity [30], which results in
increased expression of many downstream target genes that
contribute to tumor malignancy [31]. Activation of HIF-1 signal
transduction in GBM appears to be initiated through a vicious
cycle of poorly functioning vasculature that perpetuates the
development of chronic or cycling hypoxic regions throughout
the tumor [32]. Since it is difficult to explore the naturally
occurring variation of different hypoxia-induced responses, we
used a direct experimental technique to modify tumor oxygenation
and induce additional chronic or cycling hypoxia in tumors. With
this approach, we can directly observe the effects of chronic and
cycling hypoxia on relevant responses or mechanisms in living
subjects. In addition, the dynamics of HIF-1 signal transduction
activity mediated by cyclic hypoxia in a tumor is fast due to the
instability of the HIF-1a protein under reoxygenation; a reporter
gene with a high temporal resolution is required for monitoring
such dynamic processes [20]. Although TKGFP has been used for
monitoring temporal dynamics and spatial heterogeneity of HIF-1
signal transduction within tumors in living subjects, its use is
impractical for real-time monitoring of the dynamics of activity
mediated by hypoxia and reoxygenation in tumors because of its
poor temporal resolution [21]. To more faithfully reflect the
dynamics of HIF-1 signal transduction activity mediated by cyclic
hypoxia in vitro and in vivo, we developed a modified TKGFP
Table 1. Quantitative data obtained from microPET imaging and in vivo optical imaging of HIF-1 transcriptional activity in
GBM8401/hif-1-r tumors with or without Tempol treatment.
MicroPET Imaging (% ID/g) In Vivo Optical Imaging (610
9 p/s/cm
2/sr)
Normoxia 0.4660.12 0.4360.17
Cycling hypoxia 1.3260.48* 1.1360.42*
Cycling hypoxia+Tempol 0.5760.21 0.5260.18
Each value represents the mean 6 standard deviation (SD) of the values obtained from 6 mice.
*p,0.01 compared to normoxia.
doi:10.1371/journal.pone.0023945.t001
Figure 5. The majority of HIF-1 signal transduction activity and Nox4 expression occurs in endogenous cycling hypoxic areas in a
solid tumor. (A) Representative images of microscopic GBM8401/hif-1-r xenografts. Upper left, fluorescence image of DsRed reporter (red),
indicating tumor cell localization within the brain. Upper right, fluorescence image of Hoechst 33342 (blue) showing perfusion within the brain and
tumor tissue. Lower left, fluorescence image of GFP reporter (green), demonstrating HIF-1 transcriptional activity in tumor cells. Lower middle,
fluorescence image of Nox4 staining (red). Lower right, fluorescence overlay image of Hoechst 33342 (blue), GFP reporter (green), and Nox4 (red). Bar,
50 mm. (B) Scatterplots by 2-color staining with Hoechst 3342 and GFP. (C) Mean channel fluorescence of Nox4 staining was determined in cycling
hypoxic cells (Hoechst 3342
+ and GFP
+), chronic hypoxic cells (Hoechst 3342
2 and GFP
+), and normoxic cells (Hoechst 3342
+ and GFP
2) as gated in
scatterplots by Hoechst 3342 and GFP staining.
doi:10.1371/journal.pone.0023945.g005
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spatial heterogeneity of HIF-1 signal transduction activity in
tumors. In this study, in vitro and in vivo data clearly demonstrate
that GBM cells or GBM-bearing mice exposed to cycling hypoxia
induce more prolonged and higher tumor HIF-1 signal transduc-
tion activity than that of non-interrupted hypoxia. Our in vivo
results validate the in vitro results derived from earlier studies
[4,6,33] and suggest that cycling hypoxia, like chronic hypoxia,
can induce HIF-1 transcriptional activity in living subjects.
Although in vitro or in vivo hypoxic treatments of tumor cells or
xenografts can provide indirect evidence of the biosignature of
cycling hypoxic cells in vivo, it is best to directly validate these
biosignatures in the endogenous tumor microenvironment. We
have established a reliable protocol of cycling hypoxic cell
identification that allows subsequent immunofluorescence imag-
ing or flow cytometric analysis of the biosignature in these cells.
We modified a technique based on a previously reported protocol
[34,35]. This technique utilizes the diffusion/consumption
properties of Hoechst 3342 when it passes through several cell
layers and can separate tumor cells as a function of their distance
from the blood supply. However, the original technique cannot
be used to distinguish or isolate cycling hypoxic cells and chronic
hypoxic cells from a heterogeneous population of tumor cells in
the solid tumor due to a lack of a cycling hypoxic biomarker.
Here, we identify these cells according to the physiological and
molecular characteristics of cycling hypoxia. Cycling hypoxia
tended to occur in highly vascular regions with relatively high
permeability and therefore, cycling hypoxic areas still have blood
perfusion after transient occlusion or narrowing of the vasculature
[5,36]. In contrast, chronic hypoxic areas do not have blood
perfusion, even when the blood perfusion of the areas proximal to
the blood vessels has been restored. Therefore, the perfusion
marker, Hoechst 33342, stains positive in both normoxic and
cycling hypoxic cells within solid tumors when the marker is
injected into living mice and permitted to circulate for a period of
time [34]. Moreover, it has been shown that cells exposed to
cycling hypoxia exhibit more robust HIF-1 activation than cells
that are chronically hypoxic [6,33,37]. Therefore, reporter gene
expression is induced by HIF-1 activation in both cycling and
chronic hypoxic cells within solid tumors. Cells that are positive
for Hoechst 33342 staining and HIF-1 activation are potential
cycling hypoxic cells. Therefore, the combination of Hoechst
33342 staining and HIF-1 activation labeling, together with
immunofluorescence imaging or flow cytometric analysis, is an
effective approach to identifying hypoxic heterogeneous popula-
tions in solid tumors.
The effects of chronic hypoxia on HIF-1 regulation have been
extensively studied, and it is clear that chronic hypoxia can
stabilize HIF-1a due to blockage of the degradation pathway,
further inducing its signal transduction activity [38]. Recently, it
has been shown that cells exposed to cycling hypoxia exhibit a
more robust HIF-1 response than cells that are chronically
hypoxic [6]. The results from earlier works, as well as our present
results, clearly demonstrate that cells exposed to cycling hypoxia
can induce more HIF-1a protein expression and activity than they
do under non-interrupted hypoxia. Although the mechanisms of
this effect are complex and still not fully clear, ROS may play a
role in cycling hypoxia-enhanced HIF-1a protein expression and
signal transduction activity [4]. In our current work, in vitro and in
vivo results confirmed that ROS is required for cycling hypoxia-
induced HIF-1 activation and the antioxidant compound,
Tempol, inhibited cycling hypoxia-induced HIF-1 signal trans-
duction activity. Although the mechanism of ROS-mediated HIF-
1 signal transduction activity under cycling hypoxia is still not
defined, 2 mechanisms for ROS-mediated HIF-1 activation have
been suggested. One possibility is that ROS stabilizes HIF-1a.
Early studies demonstrated that the production of ROS under
normoxia stabilizes HIF-1a and contributes to HIF-1 activation
[39]. The other possibility is that ROS depolymerizes stress
granules and further enhances downstream HIF-1 signaling [40].
Pioneer studies showed that a pool of HIF-1-regulated transcripts
were kept untranslated in the course of hypoxia in stress granules
that were depolymerized during reoxygenation, allowing the rapid
translation of sequestered transcripts under normoxia. These
mechanisms could also explain, at least in part, how ROS
enhances HIF-1 activation and transduction activity under cycling
hypoxia.
In earlier studies, cycling hypoxia-promoted tumor invasion was
found in animal models [7,8]. However, the different tumor
growth rates between cycling hypoxia-treated mice and control
mice were observed in human cervical carcinoma-bearing mice
but not in KHT tumor-bearing mice, suggesting that cycling
Figure 6. Cycling hypoxia promotes tumor growth via Nox4-
mediated ROS in GBM xenografts. (A) The mean normalized BLI
values associated with longitudinal monitoring of intracranial tumor
growth for each treatment group. Mice bearing 12-d orthotopic
GBM8401-Luc xenografts were treated daily with Dox-inducible Nox4
knockdown or 100 mg/kg Tempol following in vivo cycling hypoxia
treatment for 24 days. Bars report the mean 6 standard deviation of
measurements in 6 mice. (B) The corresponding survival curves of
GBM8401-Luc xenograft-bearing mice exposed to daily treatment with
Dox-inducible Nox4 knockdown or Tempol following in vivo cycling
hypoxia treatment. * p,0.01 compared to normoxia.
doi:10.1371/journal.pone.0023945.g006
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our knowledge, the impact of cycling hypoxia on tumor
progression in GBM has not been investigated. In this study, we
found that cycling hypoxia promoted tumor growth in GBM.
Importantly, we have also demonstrated that Nox4 and ROS are
crucial mediators in cycling hypoxia-promoted tumor growth.
Nox4 knockdown or Tempol treatment suppressed tumor ROS
and tumor growth in cycling hypoxia-treated mice and control
mice. Recently, it has been shown that endogenous ROS play an
important role in angiogenesis and tumor growth [10]. Many
cancer cells show increased levels of ROS via genetic alternations
or growth factors. The increased ROS could modulate signaling
pathways and transcription factors for tumor initiation and
progression. Here, we highlighted how the tumor microenviron-
ment, cycling hypoxia, increased tumor cell ROS via Nox4 and
further promoted tumor growth in GBM. Blockage of ROS
production via Nox4 shRNA or Tempol treatment inhibits
endogenous tumor microenvironment or exogenous cycling
hypoxia-mediated tumor growth, suggesting that ROS play crucial
roles in the promotion of tumor growth induced by cycling
hypoxia. Although it is possible that other ROS-mediated
signaling pathways are involved, we report here that ROS play
important roles in cycling hypoxia-mediated HIF-1activation and
further promote tumor progression in GBM. This information
may be useful to understanding new mechanisms of tumor
microenvironment-promoted tumorigenesis and to develop new
therapeutic strategies by targeting ROS signaling in human GBM.
Conclusion
Cycling hypoxia-induced ROS via Nox4 is a critical aspect of
cancer biology to consider for therapeutic targeting of HIF-1
activation and cancer progression in GBM.
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